Clinical Trials Logo

Minimal Residual Disease clinical trials

View clinical trials related to Minimal Residual Disease.

Filter by:

NCT ID: NCT01751425 Terminated - Clinical trials for Minimal Residual Disease

Ruxolitinib in Treating Participants With Chronic Myeloid Leukemia With Minimal Residual Disease While on Therapy With Tyrosine Kinase Inhibitors

Start date: July 24, 2013
Phase: Phase 1
Study type: Interventional

This phase I/II trial studies the side effects and best dose of ruxolitinib and to see how well it works in participants with chronic myeloid leukemia with minimal residual disease while on therapy with tyrosine kinase inhibitors. Ruxolitinib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth.

NCT ID: NCT01158885 Terminated - Clinical trials for Minimal Residual Disease

Clofarabine With Cytarabine for Patients With Minimal Residual Disease Positive Leukemia

Start date: August 2010
Phase: Phase 2
Study type: Interventional

This study will test the ability of clofarabine + cytarabine to eliminate minimal residual disease (MRD) in acute myelogenous leukemia (AML) and acute lymphoblastic leukemia (ALL) patients whose bone marrows exhibit complete remission by morphology. The toxicity profile of this regimen will be evaluated in addition to toxicity experienced by patients who proceed to stem cell transplant. Overall length of remission will also be collected.

NCT ID: NCT00267085 Completed - Clinical trials for Chronic Myeloid Leukemia

Synthetic Vaccine in Patients With Chronic Myeloid Leukemia and Minimal Residual Disease

Start date: December 2005
Phase: Phase 2
Study type: Interventional

The goal of this clinical research study is to learn if giving 1 of 2 CML (Chronic Myeloid Leukemia) vaccines (CML-VAX B2 or CML-VAX B3) together with imatinib mesylate can decrease or eliminate all evidence of disease in patients who have CML that is in remission after treatment with imatinib mesylate, but who still have small amounts of detectable disease.